scholarly journals Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy

2004 ◽  
Vol 48 (5) ◽  
pp. 1727-1732 ◽  
Author(s):  
Matthew K. Schinabeck ◽  
Lisa A. Long ◽  
Mohammad A. Hossain ◽  
Jyotsna Chandra ◽  
Pranab K. Mukherjee ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Treatment Strategy ◽  
Liposomal Amphotericin ◽  
Rabbit Model ◽  
Liposomal Amphotericin B ◽  
Electron Microscopic ◽  
Lock Therapy ◽  
Antifungal Lock Therapy ◽  
Scanning Electron

ABSTRACT Catheter-related infections due to Candida albicans biofilms are a leading cause of fungal nosocomial bloodstream infection. In this paper, we describe the development of a model of catheter-associated infection with C. albicans biofilms and show that antifungal lock therapy with liposomal amphotericin B is an effective treatment strategy for these infections. Silicone catheters surgically placed in New Zealand White rabbits were infected with C. albicans, and the rabbits were randomized into three groups: (i) untreated controls, (ii) liposomal amphotericin B lock, and (iii) fluconazole lock. Upon completion of therapy, blood cultures were obtained and the catheters were removed for quantitative culture and scanning electron microscopic analyses. Quantitative cultures revealed that catheters treated with liposomal amphotericin B yielded 0 CFU, which was significant compared to the untreated controls (P < 0.001) and the fluconazole-treated group (P = 0.0079). Although fluconazole treatment tended to have lower CFU compared to untreated controls, there was no difference in mean colony counts between these two groups (1.128 ± 0.764 and 1.841 ± 1.141 log10 CFU/catheter segment, respectively; P = 0.297). Scanning electron microscopy revealed abundant biofilm in the control and fluconazole groups, while the liposomal amphotericin B group was virtually cleared. These findings suggest a possible treatment strategy for the successful salvage of catheters infected with C. albicans biofilms and describe an animal model that may play an important role in the further study of C. albicans biofilm pathogenesis and evaluation of potential antibiofilm agents.

scholarly journals Antifungal Lock Therapy With Liposomal Amphotericin B: A Prospective Trial

2014 ◽  
Vol 5 (1) ◽  
pp. 80-84 ◽  
Author(s):  
William McGhee ◽  
Marian G. Michaels ◽  
Judith M. Martin ◽  
George V. Mazariegos ◽  
Michael Green
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Prospective Trial ◽  
Liposomal Amphotericin B ◽  
Lock Therapy ◽  
Antifungal Lock Therapy

scholarly journals Caspofungin at Catheter Lock Concentrations Eradicates Mature Biofilms of Candida lusitaniae and Candida guilliermondii

2014 ◽  
Vol 58 (8) ◽  
pp. 4953-4956 ◽  
Author(s):  
Maria Simitsopoulou ◽  
Daniela Kyrpitzi ◽  
Aristea Velegraki ◽  
Thomas J. Walsh ◽  
Emmanuel Roilides
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Candida Guilliermondii ◽  
Liposomal Amphotericin B ◽  
Antibiofilm Activity ◽  
Test Species ◽  
Content Type ◽  
Lock Therapy ◽  
Catheter Lock ◽  
Candida Lusitaniae

ABSTRACTThe antibiofilm activities of caspofungin, anidulafungin, micafungin, and liposomal amphotericin B were studied againstCandida lusitaniae,Candida guilliermondii, and aCandida albicanscontrol strain. While anidulafungin and micafungin (0.007 to 2,048 mg/liter) showed reduced activity against biofilms of both test species, caspofungin displayed concentration-dependent antibiofilm activity, reaching complete and persistent eradication at concentrations achievable during lock therapy (512 to 2,048 mg/liter,P< 0.05). Although liposomal amphotericin B strongly inhibited mature biofilms, it possessed lower antibiofilm activity than caspofungin (P< 0.05).

Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits

2010 ◽  
Vol 56 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Yudum Tiftikcioğlu Deren ◽  
Şengül Özdek ◽  
Ayşe Kalkanci ◽  
Nalan Akyürek ◽  
Berati Hasanreisoğlu
Keyword(s):  
Candida Albicans ◽  
Minimum Inhibitory Concentration ◽  
Amphotericin B ◽  
Combination Treatment ◽  
Liposomal Amphotericin ◽  
Inhibitory Concentration ◽  
Liposomal Amphotericin B ◽  
Control Group

The goal of this study was to compare in vitro and in vivo efficacy of moxifloxacin and liposomal amphotericin B (Amp-B) monotherapies and combination treatment against Candida albicans in an exogenous endophthalmitis model in rabbit eyes. Microplate dilution tests and checkerboard analysis were performed to detect in vitro efficacies. Endophthalmitis was induced by intravitreal injection of C. albicans in 40 rabbit eyes with simultaneous intravitreal drug injection according to prophylactic treatment groups. Group 1 (control group) received 0.1 mL of balanced salt solution, group 2 (moxi group) 100 µg moxifloxacin/0.1 mL, group 3 (Amp-B group) 10 µg liposomal Amp-B/0.1 mL, and group 4 (combi group) both 100 µg moxifloxacin/0.05 mL and 10 µg liposomal Amp-B/0.05 mL intravitreally. Clinical examination, quantitative analysis of microorganisms, and histopathologic examination were performed as in vivo studies. The minimum inhibitory concentration of liposomal Amp-B against C. albicans was found to be 1 µg/mL. Moxifloxacin showed no inhibition of in vitro C. albicans growth. The minimum inhibitory concentration values of liposomal Amp-B for C. albicans were reduced two- to eightfold with increasing concentrations of moxifloxacin in vitro. In vivo, there was no C. albicans growth in the combi group (zero of eight eyes), whereas three eyes (37.5%) showed growth in the Amp-B group. Vitreous inflammation, retinal detachment, focal retinal necrosis, and outer nuclear layer loss were found to be lower in the moxi group compared with the control group. Ganglion cell and inner nuclear layer loss was observed in all eyes (100%) in both the moxi and combi groups, whereas only in 25% (two of eight eyes) in the Amp-B group. Moxifloxacin strongly augments the efficacy of liposomal Amp-B against C. albicans in vitro, although it has no in vitro antifungal activity when used alone. It is interesting that we found a synergistic effect for in vitro tests but failed to demonstrate it in vivo. When 100 µg moxifloxacin/0.1 mL is given intravitreally, it has some toxic effects that are limited to the inner retinal layers.

scholarly journals RecurrentCandida albicansVentriculitis Treated with Intraventricular Liposomal Amphotericin B

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Demet Toprak ◽  
Sevliya Öcal Demir ◽  
Eda Kepenekli Kadayifci ◽  
Özden Türel ◽  
Ahmet Soysal ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Lymphoblastic Leukemia ◽  
Liposomal Amphotericin B ◽  
Cns Infection ◽  
High Morbidity ◽  
Favorable Result ◽  
Resonance Imaging ◽  
Magnetic Resonance Imaging Mri

Central nervous system (CNS) infection withCandidais rare but significant because of its high morbidity and mortality. When present, it is commonly seen among immunocompromised and hospitalized patients. Herein, we describe a case of a four-year-old boy with acute lymphoblastic leukemia (ALL) who experienced recurrentCandida albicansmeningitis. The patient was treated successfully with intravenous liposomal amphotericin B at first attack, but 25 days after discharge he was readmitted to hospital with symptoms of meningitis.Candida albicanswas grown in CFS culture again and cranial magnetic resonance imaging (MRI) showed ventriculitis. We administered liposomal amphotericin B both intravenously and intraventricularly and favorable result was achieved without any adverse effects. Intraventricular amphotericin B may be considered for the treatment of recurrent CNSCandidainfections in addition to intravenous administration.

Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans

1995 ◽  
Vol 36 (6) ◽  
pp. 961-974 ◽  
Author(s):  
E. W. M. van Etten ◽  
H. R. Chander ◽  
S. V. Snijders ◽  
I. A. J. M. Bakker-Woudenberg
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B
Sign in / Sign up

Export Citation Format

Share Document